TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15208586

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone, 500 microg twice daily for 14 days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 10937294

Group type: EXPERIMENTAL
Intervention: Analogy tasks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Phonological decoding abilities
Number of subjects: 40
Study: 9636522

Group type: COMPARATOR
Intervention: MMF 1 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMF 2 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMF 2 g (mean dose adjusted to 1.5 g by 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: AZA
Number of subjects: 0
Study: 8160943

Group type: COMPARATOR
Intervention: Fentanyl 5 micrograms.kg-1 at induction and another 4 micrograms.kg-1 before skin incision (group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fentanyl (same dose) plus clonidine 4 micrograms.kg-1 in 20 min + 2 micrograms.kg-1.h-1 (group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fentanyl plus clonidine (same dosage) plus lignocaine 2 mg.kg-1 before skin incision, repeated before peritoneal incision and retractor placement (group C)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fentanyl plus clonidine (same dosage) plus lignocaine 2 mg.kg-1 before skin incision, repeated before peritoneal incision and retractor placement (group D)
Number of subjects: 80
Study: 2829492

Group type: EXPERIMENTAL
Intervention: Antileukaemic protocol
Number of subjects: 0
Study: 31586244

Group type: EXPERIMENTAL
Intervention: taTME
Number of subjects: 261

Group type: COMPARATOR
Intervention: laTME
Number of subjects: 261
Study: 31077432

Group type: EXPERIMENTAL
Intervention: PK-guided dosing of paclitaxel
Number of subjects: 319

Group type: COMPARATOR
Intervention: BSA-based dosing of paclitaxel
Number of subjects: 319
Study: 28259326

Group type: EXPERIMENTAL
Intervention: Low-dose screening chest CT
Number of subjects: 17309
Study: 25232856

Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 669

Group type: COMPARATOR
Intervention: In-person counseling
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Telephone counseling for minority women
Number of subjects: 669
Study: 23850386

Group type: EXPERIMENTAL
Intervention: 0.1% capsaicin applied on the skin of the thigh
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo cream applied on the contralateral thigh
Number of subjects: 18
Study: 21346159

Group type: EXPERIMENTAL
Intervention: Moderate dose remifentanil (0.2 μg · kg(‐1) · min(‐1))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High dose remifentanil (0.4 μg · kg(‐1) · min(‐1))
Number of subjects: 60
Study: 18432177

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES) with antiproliferative drugs attached via polymers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 0
Study: 17065539

Group type: EXPERIMENTAL
Intervention: Balance training using force platform biofeedback (15 sessions)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional stroke inpatient rehabilitation programme
Number of subjects: 41
Study: 12763708

Group type: EXPERIMENTAL
Intervention: Chemical trigger exposure
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo exposure
Number of subjects: 36
Study: 14596755

Group type: COMPARATOR
Intervention: Conservative management (no active intervention)
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 755
Study: 11206016

Group type: EXPERIMENTAL
Intervention: Early invasive approach
Number of subjects: 8000

Group type: COMPARATOR
Intervention: Conservative approach
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Early invasive strategy (VANQWISH trial)
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Routine invasive approach (OASIS registry)
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Ischemia-guided strategy (GUSTO-IIB and PURSUIT trials)
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Assigned revascularization (FRISC II trial)
Number of subjects: 8000
Study: 8666176

Group type: EXPERIMENTAL
Intervention: Dobutamine echocardiography (TED) with incremental dobutamine infusion: 5 to 40 ncg/kg/min, continued with atropine 0.25 to 1 mg iv if necessary
Number of subjects: 130

Group type: COMPARATOR
Intervention: Maximal bicycle exercise electrocardiography (TE)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Combination of TED and TE results
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: TED
Number of subjects: 130
Study: 1632167

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (0.003 and 0.0075 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Atropine (0.006 and 0.015 mg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 100
Study: 6544449

Group type: EXPERIMENTAL
Intervention: Intervention group (social medical intervention by nurses experienced in geriatrics)
Number of subjects: 4128

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 4128

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 4128

Group type: COMPARATOR
Intervention: Intervention group and Control group
Number of subjects: 4128
Study: 3554881

Group type: EXPERIMENTAL
Intervention: Fusidic acid 1% eye drops
Number of subjects: 250

Group type: COMPARATOR
Intervention: Chloramphenicol 0.5% eye drops
Number of subjects: 250
Study: 30971282

Group type: EXPERIMENTAL
Intervention: Tubeless single-port video-assisted thoracic surgery (Tubeless‐SPVATS) via anterior mediastinum
Number of subjects: 18
Study: 28986425

Group type: EXPERIMENTAL
Intervention: e‐Consent
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional consent
Number of subjects: 47
Study: 25980345

Group type: EXPERIMENTAL
Intervention: Adjunctive raloxifene treatment (120 mg per day)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 23731173

Group type: EXPERIMENTAL
Intervention: Home exercise group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Education group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Supervised exercise group
Number of subjects: 60
Study: 22289524

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with docetaxel, cisplatin and 5-fluorouracil/leucovorin (NCT group)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Postoperative chemotherapy alone (non-NCT group)
Number of subjects: 55
Study: 18065570

Group type: EXPERIMENTAL
Intervention: Community-based physical activity intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 16400334

Group type: COMPARATOR
Intervention: Ceftazidime (n = 74 patients, group I)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (n = 87 patients, group II)
Number of subjects: 219
Study: 15228463

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide IV
Number of subjects: 58

Group type: COMPARATOR
Intervention: 0.4 mg/kg metoclopramide IV (up to 32 mg)
Number of subjects: 58
Study: 11390121

Group type: EXPERIMENTAL
Intervention: Aerodiol 300 microg, once daily
Number of subjects: 408

Group type: COMPARATOR
Intervention: Oral estradiol 2 mg/day
Number of subjects: 408
Study: 9245039

Group type: EXPERIMENTAL
Intervention: IGF‐I
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: IGFBP‐3
Number of subjects: 337
Study: 8426213

Group type: EXPERIMENTAL
Intervention: DNA ploidy analysis
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: %S greater than 12.3 as a prognostic variable
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: %S adjusted for clinical characteristics
Number of subjects: 502
Study: 2890156

Group type: EXPERIMENTAL
Intervention: Psychoactive agents
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 31431385

Group type: EXPERIMENTAL
Intervention: Postoperative whole breast irradiation (WBI) + Tumour bed boost (TBB) (16 Gy in 8 fractions)
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Hypofractionated WBI (42.5 Gy in 16 fractions)
Number of subjects: 1608

Group type: COMPARATOR
Intervention: Conventional WBI (50 Gy in 25 fractions)
Number of subjects: 1608
Study: 30423197

Group type: EXPERIMENTAL
Intervention: Any HAC‐OP
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: HAC‐OP
Number of subjects: 434
Study: 27999851

Group type: COMPARATOR
Intervention: Placebo (Lecithin, 2400 mg daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (eicosapentaenoic acid (EPA); 1770 mg, and docosahexaenoic acid (DHA); 390 mg, daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vitamin D (1,000 IU daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All groups (Placebo, Omega-3, Vitamin D)
Number of subjects: 24
Study: 26210542

Group type: EXPERIMENTAL
Intervention: IPFA: 2 extra professionally-delivered fluoride applications per year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NOCTP: non-operative caries treatment programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 0
Study: 22367681

Group type: EXPERIMENTAL
Intervention: Core‐FM symptoms
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Distress
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Combined index of symptom severity (the CODI)
Number of subjects: 216
Study: 20971128

Group type: EXPERIMENTAL
Intervention: EX(1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EX(2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: SED
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EX(1), EX(2), SED
Number of subjects: 12
Study: 18429857

Group type: EXPERIMENTAL
Intervention: Dried fascia
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fresh fascia
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dried and rehydrated fascia
Number of subjects: 150
Study: 16942960

Group type: EXPERIMENTAL
Intervention: Mental reinstatement of the treatment context before follow-up test
Number of subjects: 48

Group type: COMPARATOR
Intervention: Exposure therapy in one of two contexts
Number of subjects: 48
Study: 12940592

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GK501) 120 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 11098268

Group type: EXPERIMENTAL
Intervention: Pefloxacin plus vancomycin
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Pefloxacin alone
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 9249121

Group type: EXPERIMENTAL
Intervention: Ketoprofen (1.5 mg/kg) + Morphine (0.1 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Morphine (0.1 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ketoprofen (1.5 mg/kg)
Number of subjects: 12
Study: 8322695

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg sublingually)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg orally)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.5 mg sublingually)
Number of subjects: 9
Study: 3011329

Group type: EXPERIMENTAL
Intervention: Enalapril (10‐40 mg/day, p.o., for 6 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg/day, p.o.) alone for 2 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg/day, p.o.) in combination with propranolol (80‐160 mg/day, p.o.) for 4 weeks
Number of subjects: 14
Study: 30938299

Group type: EXPERIMENTAL
Intervention: Maternal Tdap vaccination at 30–32 weeks of pregnancy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (Tdap vaccination within 48 h after delivery)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Maternal Tdap vaccination
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118
Study: 29077468

Group type: EXPERIMENTAL
Intervention: Randomization of the pseudodipolar interaction in the spin-orbit-generated low-energy Hamiltonian
Number of subjects: 0

Group type: COMPARATOR
Intervention: Absence of quenched disorder
Number of subjects: 0
Study: 26587088

Group type: EXPERIMENTAL
Intervention: NPS EMS length‐based pediatric emergency resuscitation tape
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard methods to determine medication dosing (control)
Number of subjects: 20
Study: 22682471

Group type: EXPERIMENTAL
Intervention: Fragmented sleep
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-fragmented sleep
Number of subjects: 12
Study: 20638190

Group type: EXPERIMENTAL
Intervention: PENTOCLO (800 mg pentoxifylline, 1,000 IU vitamin E, and 1,600 mg clodronate 5 days per week alternating with 20 mg prednisone and 1,000 mg ciprofloxacin 2 days per week)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: PENTOCLO
Number of subjects: 54
Study: 19705519

Group type: EXPERIMENTAL
Intervention: Five sessions of individual and family counseling (+ prn ad hoc counseling)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 155
Study: 16679904

Group type: EXPERIMENTAL
Intervention: NewYork‐Presbyterian Dexterity Glove (NYPDG)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard, custom‐made pressure glove
Number of subjects: 18
Study: 15324522

Group type: EXPERIMENTAL
Intervention: fenofibrate 200 mg + ezetimibe 10 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: fenofibrate 200 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: ezetimibe 10 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study: 10926898

Group type: EXPERIMENTAL
Intervention: Red wine extract (1 g/day, equivalent to 375 mL of red wine)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Quercetin (30 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: COMPARATOR
Intervention: Washout
Number of subjects: 21
Study: 9366937

Group type: EXPERIMENTAL
Intervention: 3% end‐tidal desflurane increased to 6% and then 9% for 15‐min intervals in group 2 (intervention group).
Number of subjects: 15

Group type: COMPARATOR
Intervention: 3% end‐tidal desflurane maintained for 60 min in group 1 (control group).
Number of subjects: 15
Study: 8359587

Group type: EXPERIMENTAL
Intervention: Recombinant insulin-like growth factor I (40 micrograms/kg body weight)
Number of subjects: 9
Study: 3024866

Group type: EXPERIMENTAL
Intervention: Loperamide (16 mg orally)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low dose naloxone infusion (180 min after loperamide administration)
Number of subjects: 8
Study: 30741866

Group type: EXPERIMENTAL
Intervention: No-device group (ND); no electronic devices could be used after dinner or overnight
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (CON); unrestricted electronic device use
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: No-device group (ND)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Triathletes (ND)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 49
Study: 30485922

Group type: EXPERIMENTAL
Intervention: Whole soybeans
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soy powder
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soybean milk
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bean curd cake
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dried bean curd stick
Number of subjects: 60

Group type: COMPARATOR
Intervention: Water
Number of subjects: 60
Study: 26912284

Group type: EXPERIMENTAL
Intervention: Conventional en masse repair
Number of subjects: 82

Group type: COMPARATOR
Intervention: Separate double-layer double-row repair
Number of subjects: 82
Study: 24937541

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO; 15 mg for 6 weeks, then 30 mg daily)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 22431401

Group type: EXPERIMENTAL
Intervention: Cognitive remediation and emotion skills training (CREST) plus treatment as usual
Number of subjects: 81

Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 81
Study: 20668284

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Group CBT
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Individual CBT
Number of subjects: 225
Study: 17699008

Group type: EXPERIMENTAL
Intervention: HPV-16/18 L1 protein viruslike particle AS04 candidate vaccine (n = 1088)
Number of subjects: 2189

Group type: COMPARATOR
Intervention: Control hepatitis A vaccine (n = 1101)
Number of subjects: 2189
Study: 16232176

Group type: EXPERIMENTAL
Intervention: PGE(1) induced labor (35 women)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Spontaneous active labor (35 women)
Number of subjects: 70
Study: 12196667

Group type: EXPERIMENTAL
Intervention: Surgery (temporal lobectomy)
Number of subjects: 10
Study: 9990561

Group type: EXPERIMENTAL
Intervention: Clozapine (300 mg/day, increased to 600 and 900 mg/day if tolerated)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional neuroleptic (initial treatment for 6 weeks)
Number of subjects: 8
Study: 7750340

Group type: EXPERIMENTAL
Intervention: Bennett Cascade 2 vaporizing humidifier
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: DAR Hygroster HME
Number of subjects: 9

Group type: COMPARATOR
Intervention: Pall Ultipor HME
Number of subjects: 9
Study: 1520205

Group type: EXPERIMENTAL
Intervention: tiaprofenic acid
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: mefenamic acid
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study: 6648051

Group type: EXPERIMENTAL
Intervention: Inspiratory resistive loading
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Expiratory resistive loading
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 20
Study: 30995952

Group type: EXPERIMENTAL
Intervention: 23-week exercise program combined with case management
Number of subjects: 419

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 419
Study: 30020330

Group type: EXPERIMENTAL
Intervention: Laser acupuncture protocol (6 sessions, 24 minutes each, over 6 weeks)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Simulated laser-acupuncture sessions
Number of subjects: 102
Study: 24423117

Group type: EXPERIMENTAL
Intervention: ≥6-portion/day F&V diet
Number of subjects: 80

Group type: COMPARATOR
Intervention: 1-portion/day F&V diet
Number of subjects: 80
Study: 22955359

Group type: EXPERIMENTAL
Intervention: L. salivarius LS01 (probiotic)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 19405020

Group type: EXPERIMENTAL
Intervention: False-evidence ploys
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expert testimony
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Demeanor ploys
Number of subjects: 0
Study: 17294204

Group type: EXPERIMENTAL
Intervention: Laser‐assisted uvulopalatoplasty (LAUP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Radiofrequency-assisted uvulopalatoplasty (RAUP)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both LAUP and RAUP
Number of subjects: 44
Study: 15383111

Group type: EXPERIMENTAL
Intervention: Five or more caesarean sections
Number of subjects: 308

Group type: COMPARATOR
Intervention: Third or fourth caesarean sections
Number of subjects: 308
Study: 11438489

Group type: EXPERIMENTAL
Intervention: 360 degrees (Nissen) fundoplication
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 270 degrees (Toupet) fundoplication
Number of subjects: 200

Group type: COMPARATOR
Intervention: Preoperative esophageal dysmotility
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Postoperative esophageal motility
Number of subjects: 200
Study: 9597052

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Doxazosin (in hypertensive patients)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo (in hypertensive patients)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Doxazosin (in normotensive patients)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo (in normotensive patients)
Number of subjects: 341
Study: 9316673

Group type: EXPERIMENTAL
Intervention: L-Dopa/benserazide
Number of subjects: 21

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 21
Study: 2465445

Group type: EXPERIMENTAL
Intervention: 3-OH-HQ 225 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3-OH-HQ 450 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3-OH-HQ 900 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28333698

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response System (PHP)
Number of subjects: 475

Group type: COMPARATOR
Intervention: Control (Injury Prevention Survey)
Number of subjects: 475
Study: 29144152

Group type: EXPERIMENTAL
Intervention: Standard treatment
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Standard and psychological treatment
Number of subjects: 158
Study: 26706860

Group type: EXPERIMENTAL
Intervention: Cognitive remediation intervention (12 sessions over 4 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard drug and non-drug antidepressive treatment (control group)
Number of subjects: 46
Study: 24749303

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lumbar paravertebral block (PVB)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no pain relief)
Number of subjects: 90
Study: 23642001

Group type: EXPERIMENTAL
Intervention: Poor neighborhood physical conditions
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Average level of behavior problems of neighborhood peers within 255 meters
Number of subjects: 261
Study: 20176914

Group type: EXPERIMENTAL
Intervention: Behavioral Activation for Latinas (BA-Latino or BAL)
Number of subjects: 10
Study: 18078762

Group type: EXPERIMENTAL
Intervention: Postconditioning (POC)
Number of subjects: 50
Study: 15677609

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 12652886

Group type: EXPERIMENTAL
Intervention: Scutellaria lateriflora
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0